Relationship between MDR1 exon 26 genotype and dosage of FK506 and acute rejection following renal transplantation
- VernacularTitle:肾移植患者的多药耐药基因外显子26基因型与术后他克莫司用量的关系
- Author:
Wei WANG
;
Xiaodong ZHANG
;
Jie DING
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Immunosuppressive agents;
Genes, MDR
- From:
Chinese Journal of Organ Transplantation
2005;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate whether the MDR1 exon 26 genotype is associated with the dosage of FK506 and acute rejection in renal transplant patients. Methods One hundred and six patients who administrated FK506 after renal transplantation were retrospectively analyzed. The patients were investigated for MDR1 genotype determined by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) assays. According to the genotype, the patients were divided into 3 subgroups, wild homozygous-CC, mutant homozygous-TT and heterozygous-CT. At 3rd, 6th and 12th month after renal transplantation, enzyme-linked immunosorbent assay (ELISA) was used to measure the FK506 whole blood concentration. Whole blood FK506 concentration per dose/kg/day and acute rejection within one month postoperation were compared among 3 subgroups. Results Of the 106 patients, 32 (30.2 %), 44 (41.5 %) and 30 (28.3 %) were carriers of CC, CT, TT in MDR1 exon 26, respectively. The whole blood FK506 concentration per dose/kg/day for patients with CC was remarkably lower that that of the patients with either CT or TT (P
